K
Kosh Agarwal
Researcher at University of Cambridge
Publications - 4
Citations - 1648
Kosh Agarwal is an academic researcher from University of Cambridge. The author has contributed to research in topics: Hepatitis C & Sofosbuvir. The author has an hindex of 3, co-authored 4 publications receiving 1445 citations. Previous affiliations of Kosh Agarwal include Queen Mary University of London & Goethe University Frankfurt.
Papers
More filters
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld,Ira M. Jacobson,Christophe Hézode,Tarik Asselah,Peter Ruane,Norbert Gruener,Armand Abergel,Alessandra Mangia,Ching-Lung Lai,Henry Lik Yuen Chan,Francesco Mazzotta,Christophe Moreno,Eric M. Yoshida,Stephen D. Shafran,William J. Towner,Tram T. Tran,John McNally,Anu Osinusi,Evguenia S. Svarovskaia,Yanni Zhu,Diana M. Brainard,John G. McHutchison,Kosh Agarwal,Stefan Zeuzem +23 more
TL;DR: Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
Journal ArticleDOI
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
Eric M. Yoshida,Paul Y. Kwo,Kosh Agarwal,Christophe Duvoux,François Durand,Markus Peck-Radosavljevic,Leslie B. Lilly,Bernard Willems,Hugo E. Vargas,Princy Kumar,Robert S. Brown,Yves Horsmans,Shampa De-Oertel,Sarah Arterburn,Hadas Dvory-Sobol,Diana M. Brainard,John G. McHutchison,Norah A. Terrault,Mario Rizzetto,Beat Müllhaupt +19 more
TL;DR: Among a small population of HCV patients with decompensated cirrhosis, virologic response to ledipasvir / sofosbuvir plus ribavirin prior to liver transplantation was maintained after transplantation, even if treatment was stopped early.
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant
Eric M. Yoshida,Paul Y. Kwo,Kosh Agarwal,Christophe Duvoux,François Durand,Markus Peck-Radosavljevic,Leslie B. Lilly,Bernard Willems,Hugo E. Vargas,Princy Kumar,Robert S. Brown,Yves Horsmans,Shampa De-Oertel,Sarah Arterburn,Hadas Dvory-Sobol,Diana M. Brainard,John G. McHutchison,Norah A. Terrault,Mario Rizzetto,Beat Müllhaupt +19 more
TL;DR: In this article, the authors evaluated outcomes of 17 patients (16 with HCV genotype 1 and 1 with genotype 4) who received up to 12 or 24 weeks of ledipasvir/sofosbuvir plus ribavirin prior to or up to the time of liver transplant in the SolAR-1 and SOLAR-2 trials.